Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRCA 6.87 +0.22(3.31%)
Will VRCA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for April 18th
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
Other News for VRCA
Understanding the Miscommunication: Clarifying Requests for Report Summaries
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharma gains as FDA lists Ycanth in Orange Book
Verrica Pharmaceuticals Announces that YCANTHâ„¢ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica announces YCANTH receives new chemical entity status